VCEL News and Press, Vericel Corporation From 11/07/23

2023-11-07 12:03:23 ET More on Vericel Vericel: A Knee-Jerk 'Hold' Worth Its Salt Seeking Alpha’s Quant Rating on Vericel Historical earnings data for Vericel Financial information for Vericel For further details see: Vericel Q3 2023 Earnin...

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Confe...

2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023. Vericel’s...

Data published in the Journal of Burn Care & Research show treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, and reduced surgery when compared to Gel Vehicle and standard of care Results demonstrate that NexoBrid is safe and well...

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid launch significantly expands the total addressable market for Vericel Burn Care CAMBRI...

2023-09-11 22:44:28 ET Summary Vericel shows strong Q2 2023 financials with $45.9M revenue and $29.9M gross profit, beating expectations and raising 2023 guidance. The company has robust liquidity with $118.8M in liquid assets, no debt, and positive cash flow, well-positioned for ...

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21 st A...

2023-08-10 08:54:45 ET Summary AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force positioned to capitalize. New automated v...

2023-08-02 15:04:02 ET Vericel Corporation (VCEL) Q2 2023 Earnings Conference Call August 2, 2023, 08:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - President and CEO Joe Mara - CFO Conference Call Participants Ryan Zim...